The activation of TGF-β-related pathways blocks the penetration of cytotoxic lymphocytes into the tumor parenchyma, while specific molecular inhibitors targeting TGF-β reshape the TME to an immunostimulatory state [19,35]. This evidence concerns the gene TGFB1 and neoplasm.